tetano
Editor, Senior Moderator
Vaccine. 2014 Jul 24. pii: S0264-410X(14)00994-3. doi: 10.1016/j.vaccine.2014.07.051. [Epub ahead of print]
Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen.
Oreshkova N1, Cornelissen LA2, de Haan CA3, Moormann RJ4, Kortekaas J5.
Author information
Abstract
Virus replicon particles are capable of infection, genome replication and gene expression, but are unable to produce progeny virions, rendering their use inherently safe. By virtue of this unique combination of features, replicon particles hold great promise for vaccine applications. We previously developed replicon particles of Rift Valley fever virus (RVFV) and demonstrated their high efficacy as a RVFV vaccine in the natural target species. We have now investigated the feasibility of using this nonspreading RVFV (NSR) as a vaccine vector using influenza virus hemagglutinin as a model antigen. NSR particles were designed to express either the full-length hemagglutinin of influenza A virus H1N1 (NSR-HA) or the respective soluble ectodomain (NSR-sHA). The efficacies of the two NSR vector vaccines, applied via either the intramuscular or the intranasal route, were evaluated. A single vaccination with NSR-HA protected all mice from a lethal challenge dose, while vaccination with NSR-sHA was not protective. Interestingly, whereas intramuscular vaccination elicited superior systemic immune responses, intranasal vaccination provided optimal clinical protection.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Hemagglutinin; Intranasal; Nonspreading; Rift Valley fever virus; Vaccine; Vector
PMID:
25066737
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25066737
Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen.
Oreshkova N1, Cornelissen LA2, de Haan CA3, Moormann RJ4, Kortekaas J5.
Author information
Abstract
Virus replicon particles are capable of infection, genome replication and gene expression, but are unable to produce progeny virions, rendering their use inherently safe. By virtue of this unique combination of features, replicon particles hold great promise for vaccine applications. We previously developed replicon particles of Rift Valley fever virus (RVFV) and demonstrated their high efficacy as a RVFV vaccine in the natural target species. We have now investigated the feasibility of using this nonspreading RVFV (NSR) as a vaccine vector using influenza virus hemagglutinin as a model antigen. NSR particles were designed to express either the full-length hemagglutinin of influenza A virus H1N1 (NSR-HA) or the respective soluble ectodomain (NSR-sHA). The efficacies of the two NSR vector vaccines, applied via either the intramuscular or the intranasal route, were evaluated. A single vaccination with NSR-HA protected all mice from a lethal challenge dose, while vaccination with NSR-sHA was not protective. Interestingly, whereas intramuscular vaccination elicited superior systemic immune responses, intranasal vaccination provided optimal clinical protection.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Hemagglutinin; Intranasal; Nonspreading; Rift Valley fever virus; Vaccine; Vector
PMID:
25066737
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25066737